Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» AbbVie Receives FDA Orphan Drug Designation for Investigational Medicine Veliparib for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer
AbbVie Receives FDA Orphan Drug Designation for Investigational Medicine Veliparib for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer
AbbVie Receives FDA Orphan Drug Designation for Investigational Medicine Veliparib for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Submitted by
admin
on November 5, 2016 - 2:10pm
Source:
Yahoo
News Tags:
AbbVie
veliparib
advanced squamous non-small cell lung cancer
Headline:
AbbVie Receives FDA Orphan Drug Designation for Investigational Medicine Veliparib for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Do Not Allow Advertisers to Use My Personal information
